66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04291781 (ClinicalTrials.gov) | April 13, 2020 | 27/2/2020 | A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy | Phase II Clinical Trial of RC18(Recombinant Human B Lymphocyte Stimulator Receptor - Antibody Fusion Protein for Injection) in the Treatment of IgA Nephropathy | IgA Nephropathy | Biological: RC18 160mg;Biological: RC18 240mg;Biological: placebo | RemeGen Co., Ltd. | NULL | Completed | 18 Years | 70 Years | All | 44 | Phase 2 | China |